Compare Supplements

Prescription-only, clinician-prescribed. Subcutaneous 0.75 mg once weekly to start, usually escalated to 1.5 mg; 3.0 mg and 4.5 mg once-weekly doses are available for additional glycemic lowering. DO NOT self-dose.

Any time

Subcutaneous once-weekly pen (Trulicity)

Prescription-only, clinician-directed. Subcutaneous. Byetta (twice-daily): 5 µg before two main meals, escalated to 10 µg after ~1 month. Bydureon (once-weekly extended-release): 2 mg subcutaneously once weekly. DO NOT self-dose.

Any time

Once-weekly extended-release injection (Bydureon)

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Prior serious hypersensitivity to dulaglutide or any GLP-1 receptor agonist

• Insulin and sulfonylureas
• Oral medications (general)
• Other GLP-1 receptor agonists

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Severe renal impairment (eGFR <30 mL/min) or end-stage renal disease — exenatide is renally cleared

• Sulfonylureas and insulin
• Oral medications (general)
• Warfarin